| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
APRE sits in the Biotechnology industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 393.9K | - | - | |
| Dir | 259.3K | - | - | |
| Dir | 48.9K | - | - | |
| CFO | 43.5K | - | - | |
| Dir | 13.4K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | Gilad Oren | President/ CEO | Buy | 28,100 | $0.89 | $25,009.00 | +8.1% | +0.5% | - | |
| Jan 30, 2026 | Hamill John P. | Srvp/ Cfo/ Prin Fin &Acct Officer | Buy | 5,700 | $0.89 | $5,073.00 | +20.6% | +0.5% | - | |
| Dec 10, 2025 | Hamill John P. | Srvp/ Cfo/ Prin Fin &Acct Officer | Buy | 5,000 | $1.17 | $5,825.00 | +22.0% | -8.9% | - | |
| Dec 10, 2025 | Duey Marc | Director | Buy | 21,459 | $1.17 | $24,999.74 | +9.1% | -8.9% | - | |
| Apr 3, 2025 | Gilad Oren | President/ CEO | Buy | 5,500 | $1.84 | $10,110.21 | +1.6% | -5.6% | -60.3% | |
| Oct 23, 2024 | Gilad Oren | President/ CEO | Buy | 500 | $3.92 | $1,957.50 | +0.2% | +3.8% | -61.0% | |
| Oct 18, 2024 | Duey Marc | Director | Sell | 6,462 | $4.58 | $29,583.04 | -2.7% | -14.9% | -64.3% | |
| Oct 16, 2024 | Duey Marc | Director | Buy | 30,000 | $4.39 | $131,700.00 | +14.3% | +3.4% | -56.0% | |
| Oct 15, 2024 | Gilad Oren | President/ CEO | Buy | 250 | $2.90 | $725.00 | - | +12.1% | -51.1% | |
| Oct 14, 2024 | Duey Marc | Director | Buy | 190 | $2.58 | $490.20 | - | +33.6% | -41.0% |